Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Wisconsin, Madison
The objective of this study is to estimate complete response rates for patients treated with this regimen, to assess overall response rates, event-free survival and overall survival; and to assess toxicities associated with R-CHOP + GM-CSF. Patients will receive 6 to 8 cycles of R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone), with GM-CSF.
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed, CD20+ B cell diffuse large cell lymphoma, with measurable or evaluable disease
Having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of CHOP or R-CHOP.